Which is more profitable, Medtronic or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals keeps more of every sale as profit.

Which grows faster, Medtronic or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals grew its sales faster in recent years.

Which is cheaper, Medtronic or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals costs less for each unit of yearly profit (lower P/E).

Which has less debt, Medtronic or Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals would need fewer years of earnings to pay off its debt.

MedtronicMDTvs

Regeneron PharmaceuticalsREGN

Medtronic vs Regeneron Pharmaceuticals stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Regeneron Pharmaceuticals is more profitable, grows faster, is cheaper for its profits and has less debt.

Side by side

	Medtronic	Regeneron Pharmaceuticals
	$132 billion	$98.8 billion
	13.2%	31.4%
	+3.8%	+11.0%
	27.4×	21.9×
	2.7 years	Net cash
	7.2%	12.6%
	3.5%	0.5%

Open Medtronic Open Regeneron Pharmaceuticals

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Medtronic vs Roche · Medtronic vs Thermo Fisher Scientific · Medtronic vs UnitedHealth · Medtronic vs AbbVie · Regeneron Pharmaceuticals vs Merck & · Regeneron Pharmaceuticals vs Roche · Regeneron Pharmaceuticals vs Thermo Fisher Scientific · Regeneron Pharmaceuticals vs UnitedHealth